What is Palivizumab Intramuscular
Palivizumab intramuscular (brand name Synagis) is a medication used to prevent respiratory syncytial virus (RSV) infection in children. RSV is a common virus that can cause severe respiratory illness in young children. Palivizumab intramuscular is given as a monthly injection to high-risk children to help prevent RSV infection.
Benefits of Palivizumab Intramuscular
and Its Uses.
Palivizumab is a monoclonal antibody that is used to prevent respiratory syncytial virus (RSV) infection in high-risk children, including those with bronchopulmonary dysplasia, congenital heart disease, and prematurity. Palivizumab is administered as an intramuscular injection.
Palivizumab is a man-made (synthetic) protein that is produced in a laboratory. It is a monoclonal antibody, which is a type of protein that is produced in a laboratory and is designed to attack a specific target. In this case, the target is the respiratory syncytial virus (RSV).
RSV is a virus that can cause serious respiratory illness, including bronchiolitis (an infection of the small airways in the lungs) and pneumonia (a serious infection of the lungs). RSV is the most common cause of bronchiolitis and pneumonia
Side Effects and Dosage of Palivizumab Intramuscular
Palivizumab is a monoclonal antibody (mAb) used to prevent respiratory syncytial virus (RSV) infection in high-risk infants and children, and also to prevent RSV infection in immunocompromised adults. Palivizumab is also used off-label to prevent other types of viral infections.
RSV is a highly contagious virus that can cause severe respiratory illness in infants and young children, and can also cause serious illness in immunocompromised adults. RSV is the leading cause of hospitalization in infants and young children in the United States, and is responsible for an estimated 125,000 deaths each year worldwide.
Palivizumab is given as an intramuscular (IM) injection. The recommended dosage for high-risk infants and children is 15 mg per kg of body weight, given as a single IM injection. The recommended dosage for immunocompromised adults is 30 mg